Advertisement

Topics

Novartis: EU Oks First-line Use Of Zykadia In ALK-positive Advanced NSCLC

01:41 EDT 29 Jun 2017 | FinanzNachrichten

BASEL (dpa-AFX) - Novartis (NVS) announced the European Commission approved expanding the use of Zykadia or ceritinib to include the first-line treatment of patients with advanced non-small cell l...

Original Article: Novartis: EU Oks First-line Use Of Zykadia In ALK-positive Advanced NSCLC

NEXT ARTICLE

More From BioPortfolio on "Novartis: EU Oks First-line Use Of Zykadia In ALK-positive Advanced NSCLC"

Quick Search
Advertisement
 

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...